Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer
Nalinikanth Kotagiri, Matthew L Cooper, Michael Rettig, Christopher Egbulefu, Julie Prior, Grace Cui, Partha Karmakar, Mingzhou Zhou, Xiaoxia Yang, Gail Sudlow, Lynne Marsala, Chantiya Chanswangphuwana, Lan Lu, LeMoyne Habimana-Griffin, Monica Shokeen, Xinming Xu, Katherine Weilbaecher, Michael Tomasson, Gregory Lanza, John F DiPersio, Samuel Achilefu, Nalinikanth Kotagiri, Matthew L Cooper, Michael Rettig, Christopher Egbulefu, Julie Prior, Grace Cui, Partha Karmakar, Mingzhou Zhou, Xiaoxia Yang, Gail Sudlow, Lynne Marsala, Chantiya Chanswangphuwana, Lan Lu, LeMoyne Habimana-Griffin, Monica Shokeen, Xinming Xu, Katherine Weilbaecher, Michael Tomasson, Gregory Lanza, John F DiPersio, Samuel Achilefu
Abstract
Most cancer patients succumb to disseminated disease because conventional systemic therapies lack spatiotemporal control of their toxic effects in vivo, particularly in a complicated milieu such as bone marrow where progenitor stem cells reside. Here, we demonstrate the treatment of disseminated cancer by photoactivatable drugs using radiopharmaceuticals. An orthogonal-targeting strategy and a contact-facilitated nanomicelle technology enabled highly selective delivery and co-localization of titanocene and radiolabelled fluorodeoxyglucose in disseminated multiple myeloma cells. Selective ablation of the cancer cells was achieved without significant off-target toxicity to the resident stem cells. Genomic, proteomic and multimodal imaging analyses revealed that the downregulation of CD49d, one of the dimeric protein targets of the nanomicelles, caused therapy resistance in small clusters of cancer cells. Similar treatment of a highly metastatic breast cancer model using human serum albumin-titanocene formulation significantly inhibited cancer growth. This strategy expands the use of phototherapy for treating previously inaccessible metastatic disease.
Conflict of interest statement
The authors declare no competing financial interests.
Figures
References
- Steeg PS. Targeting metastasis. Nat. Rev. Cancer. 2016;16:201–218. doi: 10.1038/nrc.2016.25.
- Lee DW, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014;124:188–195. doi: 10.1182/blood-2014-05-552729.
- Sipkins DA, et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature. 2005;435:969–973. doi: 10.1038/nature03703.
- Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin’s disease. International prognostic factors project on advanced Hodgkin’s disease. N. Engl. J. Med. 1998;339:1506–1514. doi: 10.1056/NEJM199811193392104.
- De Angulo G, Yuen C, Palla SL, Anderson PM, Zweidler-McKay PA. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies. Cancer. 2008;112:407–415. doi: 10.1002/cncr.23168.
- Wilcox RA, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25:1502–1509. doi: 10.1038/leu.2011.112.
- Ege H, et al. Prediction of survival using absolute lymphocyte count for newly diagnosed patients with multiple myeloma: a retrospective study. Br. J. Haematol. 2008;141:792–798. doi: 10.1111/j.1365-2141.2008.07123.x.
- Spring BQ, et al. A photoactivable multi-inhibitor nanoliposome for tumour control and simultaneous inhibition of treatment escape pathways. Nat. Nanotechnol. 2016;11:378–387. doi: 10.1038/nnano.2015.311.
- Shaffer TM, Pratt EC, Grimm J. Utilizing the power of Cerenkov light with nanotechnology. Nat. Nanotechnol. 2017;12:106–117. doi: 10.1038/nnano.2016.301.
- Hartl BA, Hirschberg H, Marcu L, Cherry SR. Activating photodynamic therapy in vitro with cerenkov radiation generated from yttrium-90. J. Environ. Pathol. Toxicol. Oncol. 2016;35:185–192. doi: 10.1615/JEnvironPatholToxicolOncol.2016016903.
- Kotagiri N, Sudlow GP, Akers WJ, Achilefu S. Breaking the depth dependency of phototherapy with Cerenkov radiation and low-radiance-responsive nanophotosensitizers. Nat. Nanotechnol. 2015;10:370–379. doi: 10.1038/nnano.2015.17.
- Kamkaew A, et al. Cerenkov radiation induced photodynamic therapy using chlorin e6-loaded hollow mesoporous silica nanoparticles. ACS Appl. Mater. Interfaces. 2016;8:26630–26637. doi: 10.1021/acsami.6b10255.
- Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat. Rev. Clin. Oncol. 2009;6:339–351. doi: 10.1038/nrclinonc.2009.44.
- Ghobrial IM. Myeloma as a model for the process of metastasis: implications for therapy. Blood. 2012;120:20–30. doi: 10.1182/blood-2012-01-379024.
- Su X, et al. Antagonizing Integrin beta3 Increases Immunosuppression in Cancer. Cancer Res. 2016;76:3484–3495. doi: 10.1158/0008-5472.CAN-15-2663.
- Kröger N, Kleeberg UR, Mross K, Edler L, Hossfeld DK. Phase II clinical trial of titanocene dichloride in patients with metastatic breast cancer. Oncol. Res. Treat. 2000;23:60–62. doi: 10.1159/000027075.
- Guo M, Sun H, McArdle HJ, Gambling L, Sadler PJ. Ti(IV) uptake and release by human serum transferrin and recognition of Ti(IV)-transferrin by cancer cells: understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry. 2000;39:10023–10033. doi: 10.1021/bi000798z.
- Buettner KM, Snoeberger RC, 3rd, Batista VS, Valentine AM. Pharmaceutical formulation affects titanocene transferrin interactions. Dalton Trans. 2011;40:9580–9588. doi: 10.1039/c1dt10805k.
- Girotti AW. Photosensitized oxidation of membrane lipids: reaction pathways, cytotoxic effects, and cytoprotective mechanisms. J. Photochem. Photobiol. B. 2001;63:103–113. doi: 10.1016/S1011-1344(01)00207-X.
- Kim J, Santos OA, Park JH. Selective photosensitizer delivery into plasma membrane for effective photodynamic therapy. J. Control. Release. 2014;191:98–104. doi: 10.1016/j.jconrel.2014.05.049.
- Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005;4:145–160. doi: 10.1038/nrd1632.
- Sarin H. Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J. Angiogenesis Res. 2010;2:1–19. doi: 10.1186/2040-2384-2-14.
- Soodgupta D, et al. Small molecule MYC inhibitor conjugated to integrin-targeted nanoparticles extends survival in a mouse model of disseminated multiple myeloma. Mol. Cancer Ther. 2015;14:1286–1294. doi: 10.1158/1535-7163.MCT-14-0774-T.
- Olson DL, Burkly LC, Leone DR, Dolinski BM, Lobb RR. Anti-alpha4 integrin monoclonal antibody inhibits multiple myeloma growth in a murine model. Mol. Cancer Ther. 2005;4:91–99.
- Kiziltepe T, et al. Rationally engineered nanoparticles target multiple myeloma cells, overcome cell-adhesion-mediated drug resistance, and show enhanced efficacy in vivo. Blood Cancer J. 2012;2:e64. doi: 10.1038/bcj.2012.10.
- Peng L, et al. Combinatorial chemistry identifies high-affinity peptidomimetics against [alpha]4[beta]1 integrin for in vivo tumor imaging. Nat. Chem. Biol. 2006;2:381–389. doi: 10.1038/nchembio798.
- Korfel A, et al. Phase I clinical and pharmacokinetic study of titanocene dichloride in adults with advanced solid tumors. Clin. Cancer Res. 1998;4:2701–2708.
- Mitchell GS, Gill RK, Boucher DL, Li C, Cherry SR. In vivo Cerenkov luminescence imaging: a new tool for molecular imaging. Philos. Trans. A Math. Phys. Eng. Sci. 2011;369:4605–4619. doi: 10.1098/rsta.2011.0271.
- Bredella MA, Steinbach L, Caputo G, Segall G, Hawkins R. Value of FDG PET in the assessment of patients with multiple myeloma. Ajr. Am. J. Roentgenol. 2005;184:1199–1204. doi: 10.2214/ajr.184.4.01841199.
- Cavo M, et al. Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group. Lancet Oncol. 2017;18:e206–e217. doi: 10.1016/S1470-2045(17)30189-4.
- Agool A, et al. Radionuclide imaging of bone marrow disorders. Eur. J. Nucl. Med. Mol. Imaging. 2011;38:166–178. doi: 10.1007/s00259-010-1531-0.
- Soodgupta D, et al. Ex vivo and in vivo evaluation of overexpressed VLA-4 in multiple myeloma using LLP2A imaging agents. J. Nucl. Med. 2016;57:640–645. doi: 10.2967/jnumed.115.164624.
- Ford CE, Hamerton JL, Barnes DW, Loutit JF. Cytological identification of radiation-chimaeras. Nature. 1956;177:452–454. doi: 10.1038/177452a0.
- Thota R, Pauff JM, Berlin JD. Treatment of metastatic pancreatic adenocarcinoma: a review. Oncology. 2014;28:70–74.
- Al-Hajeili M, Azmi AS, Choi M. Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer. Onco Targets Ther. 2014;7:187–192.
- Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Control. Release. 2008;132:171–183. doi: 10.1016/j.jconrel.2008.05.010.
- Kim C, et al. Comparison of the intraperitoneal, retroorbital and per oral routes for F-18 FDG administration as effective alternatives to intravenous administration in mouse tumor models using small animal PET/CT studies. Nucl. Med Mol. Imaging. 2011;45:169–176. doi: 10.1007/s13139-011-0087-7.
- Fueger BJ, et al. Impact of animal handling on the results of 18F-FDG PET studies in mice. J. Nucl. Med. 2006;47:999–1006.
- Thorek DL, Ogirala A, Beattie BJ, Grimm J. Quantitative imaging of disease signatures through radioactive decay signal conversion. Nat. Med. 2013;19:1345–1350. doi: 10.1038/nm.3323.
- Bernhard, Y., Collin, B. & Decreau, R. A. Redshifted Cherenkov radiation for in vivo imaging: coupling Cherenkov radiation energy transfer to multiple forster resonance energy transfers. Sci Rep7, 45063 (2017).
- Pan D, et al. A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy. Nanomedicine. 2015;10:241–251. doi: 10.2217/nnm.14.101.
Source: PubMed